<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36896705</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5-6</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Clinical testing panels for ALS: global distribution, consistency, and challenges.</ArticleTitle><Pagination><StartPage>420</StartPage><EndPage>435</EndPage><MedlinePgn>420-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2023.2173015</ELocationID><Abstract><AbstractText><i>Objective</i>: In 2021, the Clinical Genome Resource (ClinGen) amyotrophic lateral sclerosis (ALS) spectrum disorders Gene Curation Expert Panel (GCEP) was established to evaluate the strength of evidence for genes previously reported to be associated with ALS. Through this endeavor, we will provide standardized guidance to laboratories on which genes should be included in clinical genetic testing panels for ALS. In this manuscript, we aimed to assess the heterogeneity in the current global landscape of clinical genetic testing for ALS. <i>Methods</i>: We reviewed the National Institutes of Health (NIH) Genetic Testing Registry (GTR) and members of the ALS GCEP to source frequently used testing panels and compare the genes included on the tests. <i>Results</i>: 14 clinical panels specific to ALS from 14 laboratories covered 4 to 54 genes. All panels report on <i>ANG</i>, <i>SOD1</i>, <i>TARDBP</i>, and <i>VAPB</i>; 50% included or offered the option of including <i>C9orf72</i> hexanucleotide repeat expansion (HRE) analysis. Of the 91 genes included in at least one of the panels, 40 (44.0%) were included on only a single panel. We could not find a direct link to ALS in the literature for 14 (15.4%) included genes. <i>Conclusions</i>: The variability across the surveyed clinical genetic panels is concerning due to the possibility of reduced diagnostic yields in clinical practice and risk of a missed diagnoses for patients. Our results highlight the necessity for consensus regarding the appropriateness of gene inclusions in clinical genetic ALS tests to improve its application for patients living with ALS and their families.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dilliott</LastName><ForeName>Allison A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0003-3863-9304</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Nasser</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Schulich School of Medicine and Dentistry, Western University, London, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elnagheeb</LastName><ForeName>Marwa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fifita</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for MND Research, Macquarie Medical School, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henden</LastName><ForeName>Lyndal</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for MND Research, Macquarie Medical School, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keseler</LastName><ForeName>Ingrid M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>PreventionGenetics, Marshfield, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marriott</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mccann</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for MND Research, Macquarie Medical School, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mesaros</LastName><ForeName>Maysen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opie-Martin</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0951-8589</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owens</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palus</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Justyne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhanjun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Invitae, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Centre for MND Research, Macquarie Medical School, Macquarie University, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heckmann</LastName><ForeName>Jeannine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Neurology, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Amherst, Amherst, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Cristiane</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nel</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Neurology, University of Cape Town, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rampersaud</LastName><ForeName>Evadnie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center for Applied Bioinformatics, St. Jude's Children's Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roggenbuck</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouleau</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Research Unit, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Blitterswijk</LastName><ForeName>Marka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Rheenen</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Utrecht Brain Center, Utrecht, The Netherlands, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center Utrecht Brain Center, Utrecht, The Netherlands, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Heidelberg University, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drury</LastName><ForeName>Luke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>PreventionGenetics, Marshfield, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farhan</LastName><ForeName>Sali M K</ForeName><Initials>SMK</Initials><Identifier Source="ORCID">0000-0001-5936-0957</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Amyotrophic lateral sclerosis spectrum disorders Gene Curation Expert Panel</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AL-CHALABI/APR15/844-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>Z01 AG000949</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U24 HG009650</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical laboratories</Keyword><Keyword MajorTopicYN="N">gene panels</Keyword><Keyword MajorTopicYN="N">gene-disease relationships</Keyword><Keyword MajorTopicYN="N">genetic testing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>4</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36896705</ArticleId><ArticleId IdType="mid">NIHMS1900037</ArticleId><ArticleId IdType="pmc">PMC10359019</ArticleId><ArticleId IdType="doi">10.1080/21678421.2023.2173015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front Neurosci 2019;13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012;11(4):323&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, Shatunov A, Walsh C, Corr B, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012;11(3):232&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, et al. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 2016;87(10):1024&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027809</ArticleId><ArticleId IdType="pubmed">27488601</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Ray S, Srivastava A. Clinical Mimickers of Amyotrophic Lateral Sclerosis-Conditions We Cannot Afford to Miss. Ann Indian Acad Neurol 2018;21(3):173&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6137639</ArticleId><ArticleId IdType="pubmed">30258257</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D, Morren JA, Pioro EP. Time to Diagnosis and Factors Affecting Diagnostic Delay in Amyotrophic Lateral Sclerosis. In: Araki T, editor. Amyotrophic Lateral Sclerosis Brisbane (AU)2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34473440</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Scaber J, Edmond E, Marsden R, Thompson A, Talbot K, et al. Genetic testing in motor neurone disease. Pract Neurol 2022;22(2):107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938673</ArticleId><ArticleId IdType="pubmed">35027459</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon K, Anoja N, Breiner A, Chum M, Dionne A, Dupre N, et al. Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices. Amyotroph Lateral Scler Frontotemporal Degener 2022;23(3&#x2013;4):305&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">34569363</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Parker MD, Cooper-Knock J, Verber NS, Tuddenham L, Heath P, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2021;92(5):510&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry 2014;85(5):478&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med 2017;19(3):267&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">27537704</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9587202</ArticleId><ArticleId IdType="pubmed">35585374</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajda A, McLaughlin RL, Heverin M, Thorpe O, Abrahams S, Al-Chalabi A, et al. Genetic testing in ALS: A survey of current practices. Neurology 2017;88(10):991&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333513</ArticleId><ArticleId IdType="pubmed">28159885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YP, Yu SH, Wei QQ, Cao B, Gu XJ, Chen XP, et al. Role of genetics in amyotrophic lateral sclerosis: a large cohort study in Chinese mainland population. J Med Genet 2022;59(9):840&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9411893</ArticleId><ArticleId IdType="pubmed">34544842</ArticleId></ArticleIdList></Reference><Reference><Citation>Klepek H, Goutman SA, Quick A, Kolb SJ, Roggenbuck J. Variable reporting of C9orf72 and a high rate of uncertain results in ALS genetic testing. Neurol Genet 2019;5(1):e301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340336</ArticleId><ArticleId IdType="pubmed">30697590</ArticleId></ArticleIdList></Reference><Reference><Citation>Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, et al. Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. Am J Hum Genet 2017;100:895&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5473734</ArticleId><ArticleId IdType="pubmed">28552198</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinstein WS, Maglott DR, Lee JM, Kattman BL, Malheiro AJ, Ovetsky M, et al. The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res 2013;41(Database issue):D925&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3531155</ArticleId><ArticleId IdType="pubmed">23193275</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42(Database issue):D980&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3965032</ArticleId><ArticleId IdType="pubmed">24234437</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, et al. ClinVar: improvements to accessing data. Nucleic Acids Res 2020;48(D1):D835&#x2013;D44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943040</ArticleId><ArticleId IdType="pubmed">31777943</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015;347(6229):1436&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, van Doormaal PT, Dekker AM, Ticozzi N, Kenna BJ, Diekstra FP, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 2016;48(9):1037&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker AM, Diekstra FP, Pulit SL, Tazelaar GHP, van der Spek RA, van Rheenen W, et al. Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. Sci Rep 2019;9(1):5931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459905</ArticleId><ArticleId IdType="pubmed">30976013</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Topp SD, Fallini C, Shibata H, Chen HJ, Troakes C, et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med 2017;9(388).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>Teyssou E, Muratet F, Amador MD, Ferrien M, Lautrette G, Machat S, et al. Genetic screening of ANXA11 revealed novel mutations linked to amyotrophic lateral sclerosis. Neurobiol Aging 2021;99:102 e11&#x2013;e20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33218681</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainouchi M, Hatano Y, Tada M, Ishihara T, Ando S, Kato T, et al. A novel splicing variant of ANXA11 in a patient with amyotrophic lateral sclerosis: histologic and biochemical features. Acta Neuropathol Commun 2021;9(1):106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8186038</ArticleId><ArticleId IdType="pubmed">34099057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>